TRIENTINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trientine Hydrochloride, and what generic alternatives are available?
Trientine Hydrochloride is a drug marketed by Accord Hlthcare, Amneal, Chartwell Rx, Dr Reddys, Eci Pharms Llc, Hetero Labs Ltd Iii, Lupin Ltd, MSN, Navinta Llc, Par Pharm Inc, Rising, Watson Labs Teva, and Zydus Pharms. and is included in thirteen NDAs.
The generic ingredient in TRIENTINE HYDROCHLORIDE is trientine hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the trientine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trientine Hydrochloride
A generic version of TRIENTINE HYDROCHLORIDE was approved as trientine hydrochloride by WATSON LABS TEVA on February 7th, 2018.
Summary for TRIENTINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 13 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 12 |
Patent Applications: | 246 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in TRIENTINE HYDROCHLORIDE? | TRIENTINE HYDROCHLORIDE excipients list |
DailyMed Link: | TRIENTINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TRIENTINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alexion Pharmaceuticals | Phase 2 |
University of Manchester | Phase 2 |
National Institute for Health Research, United Kingdom | Phase 2 |
Pharmacology for TRIENTINE HYDROCHLORIDE
Drug Class | Metal Chelator Copper Chelator |
Mechanism of Action | Metal Chelating Activity Copper Chelating Activity |